- Home
- RRGB vs CUE Comparison
RRGB vs CUE Comparison
Compare RRGB & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RRGB | CUE |
|---|---|---|
| Founded | 1969 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.9M | 233.5M |
| IPO Year | 2002 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RRGB | CUE |
|---|---|---|
| Price | $7.46 | $27.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $9.00 | ★ $120.00 |
| AVG Volume (30 Days) | 271.3K | ★ 359.1K |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.43 | 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,315,014,000.00 | $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $2.46 | $0.17 |
| 52 Week High | $10.95 | $45.50 |
Technical Indicators
Market Signals| Indicator | RRGB | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 48.30 |
| Support Level | $6.26 | $23.51 |
| Resistance Level | $8.26 | $33.11 |
| Average True Range (ATR) | 0.45 | 4.75 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 39.89 | 31.98 |
Price Performance
Historical ComparisonAbout RRGB Red Robin Gourmet Burgers Inc.
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. The company's brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. It has one operating and one reportable segment: restaurants.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.